On October 14 (local time), Iambic Therapeutics, a pharmaceutical company propelled by artificial intelligence (AI), unveiled its initial public offering (IPO) price at $16 per share. The company intends to issue 9.375 million shares, with the goal of raising $150 million. Within a 30-day window, underwriters are granted the option to acquire an additional 1.40625 million shares. The company's shares are slated to make their debut on the Nasdaq Global Select Market on October 15, trading under the ticker symbol 'IAM'. The issuance is anticipated to conclude on October 16. Leading the IPO as co-bookrunning managers are J.P. Morgan, Jefferies, BofA Securities, and Citigroup. Iambic harnesses the power of AI, coupled with automated chemical and biological experimental techniques, to propel drug development forward. Notably, its candidate drug, IAM1363, has already reached the clinical stage. NVIDIA has previously been involved in its financing rounds.